Telesis Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 27th of September, 2024.
24 hedge funds and large institutions have $4.5M invested in Telesis Bio, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
4% less funds holding
Funds holding: 25 → 24 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
47% less call options, than puts
Call options by funds: $8K | Put options by funds: $15K
64% less capital invested
Capital invested by funds: $12.3M → $4.5M (-$7.84M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$35.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$19.5K |
| 3 |
Renaissance Technologies
New York
|
+$17K |
| 4 |
MAM
McCarthy Asset Management
Redwood Shores,
California
|
+$6.79K |
| 5 |
VF
Virtu Financial
New York
|
+$6.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$633K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$30.9K |
| 3 |
DDC
DF Dent & Co
Baltimore,
Maryland
|
-$20.8K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$19.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.45K |
TBIO Hedge Fund Activity: Q4 2023 in Review
24 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Telesis Bio, Inc. Common Stock (TBIO) for Q4 2023, worth a combined $4.5M — down 64% from $12.3M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TBIO and 7 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Millennium Management, adding an estimated $35.8K. The largest seller was Penn Capital Management, exiting entirely with an estimated $633K sold.
- 24 institutional investors held Telesis Bio, Inc. Common Stock (TBIO) as of Q4 2023, down from 25 in Q3 2023.
- Funds reported $4.5M of Telesis Bio, Inc. Common Stock stock for Q4 2023, down 64% quarter-over-quarter.
- 7 funds opened new Telesis Bio, Inc. Common Stock positions in Q4 2023 and 8 closed out, a net change of -1 holder.
- The largest Telesis Bio, Inc. Common Stock buyer in Q4 2023 was Millennium Management, an estimated $35.8K added.
- The largest Telesis Bio, Inc. Common Stock seller in Q4 2023 was Penn Capital Management, an estimated $633K sold.
Based on aggregated 13F filings for Q4 2023.